The Palace on Friday appointed Health Undersecretary Atty. Paolo Teston as the new Director General of the Food and Drug Administration (FDA).
Palace Press Officer Undersecretary Atty. Claire Castro relayed the confirmation to reporters during the sidelines of a press briefing. No explanation was provided for the replacement of Dr. Samuel Zacate as head of the agency.
Zacate previously served as the lead physician of President Ferdinand “Bongbong” Marcos Jr.
The FDA welcomed its new chief, stating that his appointment signals the start of a new chapter for the agency.
In a press release, Teston said his goal is to rebuild public trust and lead the FDA toward greater professionalism, integrity, and efficiency.
“I assume this role with a clear and urgent mandate: to raise the standard of service at the FDA—not through promises or plans alone, but through action,” he said.
Teston also shared plans to conduct a comprehensive review of the FDA’s key functions—inspection, licensing, and monitoring—to strengthen the safety of health products.
The new FDA chief said the reforms will be swift, strategic, and anchored on concrete results.
He further emphasized his commitment to the welfare of FDA personnel, vowing to pursue improvements in job security, professional development, and working conditions across the agency.
“Let us take care of our people. They are the hands on the wheel and the feet on the ground—they are key to the agency’s progress. We will listen to them, support them, and invest in their future,” Teston said.
Before his appointment to the FDA, Teston served as Undersecretary at the Department of Health, where he led the Health Regulation and Facility Development Cluster (HRFDC). This cluster oversees key bureaus including the Health Facility Development Bureau, the Health Facilities and Services Regulatory Bureau, and the Bureau of Quarantine.